Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancer

McCafferty, Marc P. J.; McNeill, R.E.; Miller, Nicola; Kerin, Michael J.

doi:10.1007/s10549-009-0429-7

Cited by 22 publications

(14 citation statements)

References 80 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although it is a heterogeneous disease, two thirds of breast cancers share the common feature of being dependent on the presence and interaction of estrogen with the nuclear estrogen receptor α (ERα) protein (2,3). Approximately 70% of invasive breast cancers express ERα in actively proliferating cells.…”

Section: Introductionmentioning

confidence: 99%

Epigenetically Deregulated microRNA-375 Is Involved in a Positive Feedback Loop with Estrogen Receptor α in Breast Cancer Cells

et al. 2010

View full text Add to dashboard Cite

Estrogen receptor α (ERα) upregulation causes abnormal cell proliferation in about two thirds of breast cancers, yet understanding of the underlying mechanisms remains incomplete. Here, we show that high expression of the microRNA miR-375 in ERα-positive breast cell lines is a key driver of their proliferation. miR-375 overexpression was caused by loss of epigenetic marks including H3K9me2 and local DNA hypomethylation, dissociation of the transcriptional repressor CTCF from the miR-375 promoter, and interactions of ERα with regulatory regions of miR-375. Inhibiting miR-375 in ERα-positive MCF-7 cells resulted in reduced ERα activation and cell proliferation. A combination of expression profiling from tumor samples and miRNA target prediction identified RASD1 as a potential miR-375 target. Mechanistic investigations revealed that miR-375 regulates RASD1 by targeting the 3′ untranslated region in RASD1 mRNA. Additionally, we found that RASD1 negatively regulates ERα expression. Our findings define a forward feedback pathway in control of ERα expression, highlighting new strategies to treat ERα-positive invasive breast tumors. Cancer Res; 70(22); 9175-84. ©2010 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

Epigenetically Deregulated microRNA-375 Is Involved in a Positive Feedback Loop with Estrogen Receptor α in Breast Cancer Cells

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Indeed, estrogen receptor signaling has now been shown to coactivate with various cofactors, such as steroid receptor coactivator 1 and peroxisome proliferator-activated receptor binding protein, induce a myriad of micro-RNAs at the nuclear level, and cross-talk with other tyrosine kinase receptors, including epidermal growth factor, HER2, and the IGF-1 receptor. 106 While endocrine therapy is already a well established treatment for metastatic breast cancer patients in multiple randomized controlled trials and meta-analyses, [107][108][109][110][111][112][113] understanding the relevant pathways involved may provide a further rationale for its use, particularly in the setting of bone metastases. In fact, current guidelines recommend endocrine therapy in preference to chemotherapy for women with hormone receptor-positive advanced breast cancer, except in the presence of rapidly progressive visceral disease, given the lower toxicity of endocrine therapy, similar overall survival when compared with chemotherapy, and slower progression of cancer in patients with endocrine-responsive disease.…”

mentioning

confidence: 99%

Optimal management of bone metastases in breast cancer patients

Wong

Pavlakis

2011

BCTT

View full text Add to dashboard Cite

Bone metastasis in breast cancer is a significant clinical problem. It not only indicates incurable disease with a guarded prognosis, but is also associated with skeletal-related morbidities including bone pain, pathological fractures, spinal cord compression, and hypercalcemia. In recent years, the mechanism of bone metastasis has been further elucidated. Bone metastasis involves a vicious cycle of close interaction between the tumor and the bone microenvironment. In patients with bone metastases, the goal of management is to prevent further skeletal-related events, manage complications, reduce bone pain, and improve quality of life. Bisphosphonates are a proven therapy for the above indications. Recently, a drug of a different class, the RANK ligand antibody, denosumab, has been shown to reduce skeletal-related events more than the bisphosphonate, zoledronic acid. Other strategies of clinical value may include surgery, radiotherapy, radiopharmaceuticals, and, of course, effective systemic therapy. In early breast cancer, bisphosphonates may have an antitumor effect and prevent both bone and non-bone metastases. Whilst two important Phase III trials with conflicting results have led to controversy in this topic, final results from these and other key Phase III trials must still be awaited before a firm conclusion can be drawn about the use of bisphosphonates in this setting. Advances in bone markers, predictive biomarkers, multi-imaging modalities, and the introduction of novel agents have ushered in a new era of proactive management for bone metastases in breast cancer.

show abstract

“…Also, it was demonstrated that estrogen can modulate miRNAs expression in breast cancer cells 119, inducing 21 miRNA, including eight let-7 family members, miRNA-98 and miRNA-21, while suppressing 7 miRNAs in MCF-7 cells. On the other hand this miRNAs may have implications in endocrine therapy resistance 120.…”

Section: Potential Biomarkers For Systemic Chemotherapy Resistancementioning

confidence: 99%

Far Beyond the Usual Biomarkers in Breast Cancer: A Review

Pultz¹,

Luz²,

Faria³

et al. 2014

J. Cancer

View full text Add to dashboard Cite

Research investigating biomarkers for early detection, prognosis and the prediction of treatment responses in breast cancer is rapidly expanding. However, no validated biomarker currently exists for use in routine clinical practice, and breast cancer detection and management remains dependent on invasive procedures. Histological examination remains the standard for diagnosis, whereas immunohistochemical and genetic tests are utilized for treatment decisions and prognosis determinations. Therefore, we conducted a comprehensive review of literature published in PubMed on breast cancer biomarkers between 2009 and 2013. The keywords that were used together were breast cancer, biomarkers, diagnosis, prognosis and drug response. The cited references of the manuscripts included in this review were also screened. We have comprehensively summarized the performance of several biomarkers for diagnosis, prognosis and predicted drug responses of breast cancer. Finally, we have identified 15 biomarkers that have demonstrated promise in initial studies and several miRNAs. At this point, such biomarkers must be rigorously validated in the clinical setting to be translated into clinically useful tests for the diagnosis, prognosis and prediction of drug responses of breast cancer.

show abstract

Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancer

Abstract: . Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancer.

Cited by 22 publications

References 80 publications

Epigenetically Deregulated microRNA-375 Is Involved in a Positive Feedback Loop with Estrogen Receptor α in Breast Cancer Cells

Epigenetically Deregulated microRNA-375 Is Involved in a Positive Feedback Loop with Estrogen Receptor α in Breast Cancer Cells

Optimal management of bone metastases in breast cancer patients

Far Beyond the Usual Biomarkers in Breast Cancer: A Review

Contact Info

Product

Resources

About